<DOC>
	<DOCNO>NCT02334254</DOCNO>
	<brief_summary>To evaluate safety combination Rivaroxaban Ticagrel versus triple antithrombotic regimen ( Vitamin K Antagonist ( VKA ) , Clopigogrel Aspirin ) patient atrial fibrillation coronary artery disease undergo percutaneous coronary intervention ( PCI ) .</brief_summary>
	<brief_title>Rivaroxaban Patients With Atrial Fibrillation Coronary Artery Disease Undergoing Percutaneous Coronary Intervention</brief_title>
	<detailed_description>This open-label ( physician participant know treatment participant receives ) , randomize ( study medication assign chance ) , multicenter clinical study assess safety combination rivaroxaban ticagrel versus triple antithrombotic regimen ( warfarin , clopigogrel aspirin ) patient , paroxysmal , persistent , permanent non-valvular atrial fibrillation ( AF ) concomitant coronary artery disease undergo percutaneous coronary intervention ( PCI ) . A target 420 participant randomize study , approximately 210 participant treatment strategy group . Primary comparison make rate major clinically relevant bleeding , assess modify International Society Thrombosis Haemostasis ( ISTH ) classification . The study consist screen phase , 12-month open-label treatment phase , end-of-treatment/early withdrawal visit . The total duration participation study participant approximately 12 month .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>longterm indication oral anticoagulation treatment ( least 1 year study ) severe coronary lesion ( least 75 % stenosis angiography fractional flow reserve low 0•80 ) indication PCI age 1880 year history intracranial bleeding ; cardiogenic shock ; contra indication use antiplatelet anticoagulation drug ; peptic ulcer previous 6 month ; thrombo cytopenia ( platelet concentration lower 50~10⁹/L ) ; major bleeding ( accord Thrombolysis Myocardial Infarction [ TIMI ] criterion ) past 12 month ; pregnancy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>safety</keyword>
	<keyword>rivaroxaban</keyword>
	<keyword>ticagrel</keyword>
	<keyword>triple antithrombotic regimen</keyword>
	<keyword>undergo PCI</keyword>
</DOC>